Research and Development ExpenseThe table below summarizes research and development expense by major project and non-project component (dollars in thousands):Three Months Ended
September 30,20102009PercentageChangeProject and non-project component:Cardiopulmonary $
14,14523.8%Share-based compensation14,14911,57722.2%Other9,0325,82954.9%Total research and development expense$
31,55129.0%Cardiopulmonary. The increase in expenses related to our cardiopulmonary programs for the quarter ended September 30, 2010 compared to the same quarter in 2009 was driven largely by increases in expenses associated with our FREEDOM-M and FREEDOM-C2 Phase III clinical trials and expenses related to our efforts to develop beraprost-MR.
Share-based compensation. The increase in share-based compensation for the quarter ended September 30, 2010 compared to the same quarter in 2009 resulted from increases in the price of our common stock, the number of outstanding awards issued under our share tracking awards plan and the time such awards had accrued toward vesting.
Other. For the quarter ended September 30, 2010, expenses incurred in connection with our investigational projects as well as personnel and overhead costs supporting our research increased primarily as a result of the opening of our new facilities in North Carolina and Maryland.
Selling, General and Administrative ExpenseThe table below summarizes selling, general and administrative expense by major category (dollars in thousands):Three Months Ended
ChangeCategory:General and administrative$
|SOURCE United Therapeutics Corporation|
Copyright©2010 PR Newswire.
All rights reserved